# Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

> **NCT00001993** · PHASE2 · COMPLETED · sponsor: **G D Searle** · enrollment: 120 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Butyldeoxynojirimycin
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00001993
- **Lead sponsor:** G D Searle
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 120 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001993, "Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00001993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*